HUTCHMED and Innovent announce positive results from FRUSICA-2 trial for treating renal cell carcinoma.

From GlobeNewswire: 2025-03-18 20:00:00

HUTCHMED and Innovent Biologics announce successful results from the FRUSICA-2 trial, showing that fruquintinib combined with sintilimab meets its primary endpoint for treating advanced renal cell carcinoma in China. The combination also received conditional approval for treating endometrial cancer in patients who failed prior therapy. The study demonstrated improvements in secondary endpoints, with full results to be presented at a scientific conference. The positive results indicate a significant advancement in treating advanced renal cell carcinoma, offering new hope to patients who have not responded well to previous therapies.



Read more at GlobeNewswire: HUTCHMED and Innovent Jointly Announce that the FRUSICA-2